{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bibby AC"],"funding":["National Institute for Health Research (NIHR)"],"pagination":["196"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9440504"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(1)"],"pubmed_abstract":["<h4>Background</h4>Malignant pleural mesothelioma (MPM) is an aggressive thoracic malignancy with a poor prognosis. Systemic immunotherapy is an effective frontline treatment for MPM, and there is a scientific rationale supporting the possible efficacy of local, i.e. intra-pleural immune modulators. Trial of intra-pleural bacterial immunotherapy (TILT) investigated the feasibility of performing a randomised trial of intra-pleural bacterial immunotherapy in people with MPM, using the trials within cohorts (TwiC) methodology.<h4>Methods</h4>TILT was a multicentre, three-armed, randomised, feasibility TwiC of intra-pleural OK432, BCG, or usual care in people with MPM. Eligible participants were identified from within the ASSESS-meso study, a prospective, longitudinal, observational cohort stu"],"journal":["Pilot and feasibility studies"],"pubmed_title":["A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) - a randomised feasibility study using the trial within a cohort (TwiC) methodology."],"pmcid":["PMC9440504"],"funding_grant_id":["DRF-2016-09-065"],"pubmed_authors":["Harvey JE","Rahman NM","Fallon JE","Gooberman-Hill R","Bibby AC","Keenan E","Day H","Zahan-Evans N","Maskell NA","Comins C"],"additional_accession":[]},"is_claimable":false,"name":"A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) - a randomised feasibility study using the trial within a cohort (TwiC) methodology.","description":"<h4>Background</h4>Malignant pleural mesothelioma (MPM) is an aggressive thoracic malignancy with a poor prognosis. Systemic immunotherapy is an effective frontline treatment for MPM, and there is a scientific rationale supporting the possible efficacy of local, i.e. intra-pleural immune modulators. Trial of intra-pleural bacterial immunotherapy (TILT) investigated the feasibility of performing a randomised trial of intra-pleural bacterial immunotherapy in people with MPM, using the trials within cohorts (TwiC) methodology.<h4>Methods</h4>TILT was a multicentre, three-armed, randomised, feasibility TwiC of intra-pleural OK432, BCG, or usual care in people with MPM. Eligible participants were identified from within the ASSESS-meso study, a prospective, longitudinal, observational cohort stu","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2026-05-28T00:57:04.802Z","creation":"2024-11-19T22:24:36.075Z"},"accession":"S-EPMC9440504","cross_references":{"pubmed":["36057634"],"doi":["10.1186/s40814-022-01156-3"]}}